The FDA approval of zanubrutinib plus obinutuzumab showed a benefit to patients with relapsed/refractory follicular lymphoma, according to Julie Vose, MD, MBA.
Approval Alert | Zanubrutinib/Obinutuzumab for Relapsed/Refractory Follicular Lymphoma
Patients with relapsed/refractory follicular lymphoma can now receive zanubrutinib plus obinutuzumab based on the data from the phase 2 ROSEWOOD trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA OKs Pembrolizumab/Enfortumab Vedotin in Muscle Invasive Bladder Cancer
2
Fertility-Sparing Surgery May Be Safe Despite Recurrence in Cervical Cancer
3
How ADCs and BiTEs Are Propelling Change in Lung Cancer
4
Novel Agent Yields Promising Results in MAPK-Associated Solid Tumors
5
